Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793996 | 1.00 | EPHX2 (0.47) | EPHX2SLC7A5ABL1TRPM8TGM2 | |
| SCHEMBL1496406 | 0.92 | IDO1 (0.39) | EPHX2SLC7A5TGM2FPR2 | |
| SCHEMBL12793992 | 0.92 | IDO1 (0.39) | EPHX2SLC7A5TGM2FPR2 | |
| SCHEMBL1496430 | 0.90 | EPHX2 (0.46) | EPHX2SLC7A5ABL1PDE2A | |
| SCHEMBL12793125 | 0.90 | EPHX2 (0.46) | EPHX2SLC7A5ABL1PDE2A | |
| SCHEMBL1128892 | 0.84 | RAB9A (0.36) | TGM2 | |
| SCHEMBL7874793 | 0.84 | RAB9A (0.36) | TGM2 | |
| SCHEMBL1128648 | 0.82 | EPHX2 (0.39) | EPHX2TGM2FPR2 | |
| SCHEMBL1128646 | 0.82 | EPHX2 (0.39) | EPHX2TGM2FPR2 | |
| SCHEMBL1128639 | 0.82 | AR (0.40) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | EPHX2 1977/4885SLC7A5 4795/4885ABL1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.